Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessStocks

Cadila Healthcare share price rises over 2% on USFDA approval to Zydus for Parkinson's drug

The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

March 30, 2020 / 11:36 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Cadila Healthcare share price rose over 2 percent intraday on March 30 after Zydus Cadila received tentative USFDA approval to market Carbidopa and Levodopa Extended-Release Capsules used for the treatment of Parkinson’s disease.

Zydus Cadila has received tentative approval from the USFDA to market Carbidopa and Levodopa Extended-Release Capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg, as per release.

The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad

This combination medication is indicated for use in the treatment of Parkinsons or Parkinson-like symptoms (such as shakiness, stiffness, and difficulty moving).

The group now has 282 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

At 11:00 hrs Cadila Healthcare was quoting at Rs 254.00, up Rs 1.20, or 0.47 percent on the BSE.

Moneycontrol News
first published: Mar 30, 2020 11:32 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347